Amarin (AMRN) Stock Drops After Pricing Public Offering

NEW YORK (TheStreet) -- Shares of Amarin   (AMRN)  were tumbling 9.41% to $3.01 in mid-morning trading after the Dublin-based biopharmaceutical company announced on Thursday that it priced its share offering at a discount to current prices.

The company will sell about 21 million shares at $2.85 each, a discount to its stock price as of Thursday morning. 

Amarin expects to generate approximately $56.1 million in proceeds from the selloff that the company anticipates will go toward funding its REDUCE-IT cardiovascular outcomes trial, as well as general corporate and working capital purposes.

The transaction is likely to close about August 16. 

AMRN Chart AMRN data by YCharts

If you liked this article you might like

Biotech Premarket Movers: Cempra, Novavax, Ionis

Tetraphase Executive Profits Hours Before Stock Plummets

5 Stocks Ready for Breakouts -- Must-See Charts

3 Stocks Under $10 Making Big Moves